King & Wood Mallesons is sought out by international life sciences and healthcare enterprises across Asia, North America, Europe and Australia. Providing comprehensive expertise to pharmaceutical, medical device and biotechnology and clinical trial clients, the team is regularly instructed on a broad range of M&A, financing, IPOs and IP protection matters. The team is spearheaded by Huang Jianwen from the Beijing office, well-versed in inbound and outbound investments, domestic and cross-border M&A and compliance. Mark Zhang is highly experienced in foreign investment, liquidation and restructuring matters, while Ting Liu assists with large-scale compliance projects involving healthcare, anti-corruption and anti-commercial bribery. Yuanyuan Zhu is equipped to handle responses to government investigations, as well as investigations and sanctions by multilateral development banks. Zhongbin Huang advises on transactions, strategic cooperation and regulatory compliance.
Legal 500 Editorial commentary
Accolades
Client satisfaction
Testimonials
Collated independently by Legal 500 research team.
- 'Our company have worked with the team on many BD transactions, and the quality of the deliverables is excellent.'
- 'They can provide professional legal advice in a timely manner, which is very helpful.'
- 'The team has distinctive business characteristics and many advantages. In business processing, they have shown excellent industry insight, and their team partners and members can accurately understand the industry operation model and regulatory points, and can provide clients with one-stop legal services in combination with legal, judicial and industry practices.'
- 'The team's comprehensive coordination in handling complex legal matters is impressive.'
- 'Mark Zhang is an outstanding partner; his experience in the industry and long-term cooperation with us can help us deal with various issues in the project in a timely manner, and the legal advice provided is very suitable for practical needs and helps us to control legal risks.'
- 'Zhongbin Huang is outstanding; he can quickly provide experience in innovative business models in the pharmaceutical industry and help us stay abreast of the latest market practices.'
Key clients
- Servier Monde
- Mölnlycke Health Care
- Servier (Tianjin) Pharmaceutical Co.ltd.
- Tibet Weixinkang Pharmaceutical Co., Ltd.
- AstraZeneca
- Bayer
- Astellas
- Novo Nordisk
- Merck
- Novartis
- Gilead Sciences
- AbbVie
Work highlights
Assisted Edwards with the asset transfer transaction with Becton Dickinson for the sale of Edwards' Critical Care product group.
Assisted Tianjin Pharmaceutical Holdings Co., Ltd. and Tianjin Pharmaceutical Da Ren Tang Group Corp., Ltd. to transfer 33% of the stake in Tianjin TSKF Pharmaceutical Co., Ltd. for RMB 4.5 billion.
Assisted AstraZeneca in defending against 31 patent invalidation challenges for the blockbluster drug dapagliflozin drug patent, achieving a comprehensive victory after three years of litigation.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Mark Zhang
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Ting Liu
Yuanyuan Zhu
Leading associates
Leading associates with regular involvement in their team's key work, and recognition from peers or clients as being ones to watch.
Zhongbin Huang
Practice head
Jianwen Huang
Other key lawyers
Mark Zhang; Ting Liu, Yuanyuan Zhu; Zhongbin Huang